TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-01

AUTHORS

V. K. Puduvalli, D. Sampath, J. M. Bruner, J. Nangia, R. Xu, A. P. Kyritsis

ABSTRACT

Patients with malignant gliomas have a poor prognosis and new treatment paradigms are needed against this disease. TRAIL/Apo2L selectively induces apoptosis in malignant cells sparing normal cells and is hence of interest as a potential therapeutic agent against gliomas. To determine the factors that modulate sensitivity to TRAIL, we examined the differences in TRAIL-activated signaling pathways in glioma cells with variable sensitivities to the agent. Apoptosis in response to TRAIL was unrelated to DR5 expression or endogenous p53 status in a panel of 8 glioma cell lines. TRAIL activated the extrinsic (cleavage of caspase-8, caspase-3 and PARP) and mitochondrial apoptotic pathways and reduced FLIP levels. It also induced caspase-dependent JNK activation, which did not influence TRAIL-induced apoptosis. Because the pro-survival PI3K/Akt pathway is highly relevant to gliomas, we assessed whether Akt could protect against TRAIL-induced apoptosis. Pretreatment with SH-6, a novel Akt inhibitor, enhanced TRAIL-induced apoptosis, suggesting a protective role for Akt. Conversely, TRAIL induced caspase-dependent cleavage of Akt neutralizing its anti-apoptotic effects. These results demonstrate that TRAIL-induced apoptosis in gliomas involves both activation of death pathways and downregulation of survival pathways. Additional studies are warranted to determine the therapeutic potential of TRAIL against gliomas. More... »

PAGES

233-243

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10495-005-6078-3

DOI

http://dx.doi.org/10.1007/s10495-005-6078-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046921353

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15711939


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis Regulatory Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Activation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "JNK Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MAP Kinase Kinase 4", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitogen-Activated Protein Kinase Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TNF-Related Apoptosis-Inducing Ligand", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puduvalli", 
        "givenName": "V. K.", 
        "id": "sg:person.01156403355.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156403355.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sampath", 
        "givenName": "D.", 
        "id": "sg:person.01231612071.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231612071.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pathology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Pathology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bruner", 
        "givenName": "J. M.", 
        "id": "sg:person.013375073077.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nangia", 
        "givenName": "J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "R.", 
        "id": "sg:person.01352651714.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352651714.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neurology, University of Ioaninna, Ioaninna, Greece", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Neurology, University of Ioaninna, Ioaninna, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kyritsis", 
        "givenName": "A. P.", 
        "id": "sg:person.014354466417.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014354466417.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/376785a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022545215", 
          "https://doi.org/10.1038/376785a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1204282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014003480", 
          "https://doi.org/10.1038/sj.onc.1204282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/5517", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010598958", 
          "https://doi.org/10.1038/5517"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202702", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036436500", 
          "https://doi.org/10.1038/sj.onc.1202702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203700", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014822552", 
          "https://doi.org/10.1038/sj.onc.1203700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046556077", 
          "https://doi.org/10.1038/sj.onc.1202561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050239579", 
          "https://doi.org/10.1038/sj.onc.1203453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.cdd.4400467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015301816", 
          "https://doi.org/10.1038/sj.cdd.4400467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/380075a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029942479", 
          "https://doi.org/10.1038/380075a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1204736", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011680283", 
          "https://doi.org/10.1038/sj.onc.1204736"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-01", 
    "datePublishedReg": "2005-01-01", 
    "description": "Patients with malignant gliomas have a poor prognosis and new treatment paradigms are needed against this disease. TRAIL/Apo2L selectively induces apoptosis in malignant cells sparing normal cells and is hence of interest as a potential therapeutic agent against gliomas. To determine the factors that modulate sensitivity to TRAIL, we examined the differences in TRAIL-activated signaling pathways in glioma cells with variable sensitivities to the agent. Apoptosis in response to TRAIL was unrelated to DR5 expression or endogenous p53 status in a panel of 8 glioma cell lines. TRAIL activated the extrinsic (cleavage of caspase-8, caspase-3 and PARP) and mitochondrial apoptotic pathways and reduced FLIP levels. It also induced caspase-dependent JNK activation, which did not influence TRAIL-induced apoptosis. Because the pro-survival PI3K/Akt pathway is highly relevant to gliomas, we assessed whether Akt could protect against TRAIL-induced apoptosis. Pretreatment with SH-6, a novel Akt inhibitor, enhanced TRAIL-induced apoptosis, suggesting a protective role for Akt. Conversely, TRAIL induced caspase-dependent cleavage of Akt neutralizing its anti-apoptotic effects. These results demonstrate that TRAIL-induced apoptosis in gliomas involves both activation of death pathways and downregulation of survival pathways. Additional studies are warranted to determine the therapeutic potential of TRAIL against gliomas.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10495-005-6078-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435611", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2478133", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1117236", 
        "issn": [
          "1360-8185", 
          "1573-675X"
        ], 
        "name": "Apoptosis", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "TRAIL-induced apoptosis", 
      "new treatment paradigm", 
      "TRAIL/Apo2L", 
      "PI3K/Akt pathway", 
      "potential therapeutic agent", 
      "anti-apoptotic effect", 
      "endogenous p53 status", 
      "novel Akt inhibitor", 
      "glioma cell lines", 
      "poor prognosis", 
      "treatment paradigm", 
      "JNK activation", 
      "malignant gliomas", 
      "protective role", 
      "malignant cells", 
      "therapeutic potential", 
      "gliomas", 
      "DR5 expression", 
      "therapeutic agents", 
      "glioma cells", 
      "p53 status", 
      "Additional studies", 
      "Akt pathway", 
      "Akt inhibitor", 
      "Akt inhibition", 
      "survival pathways", 
      "FLIP levels", 
      "mitochondrial apoptotic pathway", 
      "cell lines", 
      "apoptosis", 
      "SH-6", 
      "Akt", 
      "normal cells", 
      "apoptotic pathway", 
      "variable sensitivity", 
      "activation", 
      "death pathways", 
      "cells", 
      "pathway", 
      "patients", 
      "prognosis", 
      "agents", 
      "caspase-dependent cleavage", 
      "disease", 
      "downregulation", 
      "Apo2L", 
      "inhibitors", 
      "sensitivity", 
      "pretreatment", 
      "trails", 
      "status", 
      "expression", 
      "response", 
      "factors", 
      "levels", 
      "differences", 
      "study", 
      "role", 
      "effect", 
      "panel", 
      "lines", 
      "potential", 
      "results", 
      "cleavage", 
      "paradigm", 
      "interest"
    ], 
    "name": "TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation", 
    "pagination": "233-243", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046921353"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10495-005-6078-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15711939"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10495-005-6078-3", 
      "https://app.dimensions.ai/details/publication/pub.1046921353"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_409.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10495-005-6078-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10495-005-6078-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10495-005-6078-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10495-005-6078-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10495-005-6078-3'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      22 PREDICATES      119 URIs      101 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10495-005-6078-3 schema:about N134a43afbe6b488a876ae98b42afbcae
2 N15f41fa8e7fb4bcca5ead05acadc489d
3 N288d9bad1c1f434590a27b131e05f994
4 N338d23b582304d10b3d108286e197c7f
5 N35bbce0006c94e19a66fc384de39a909
6 N41719eb3db5c425ababbac7eca97320b
7 N43a06b49f0244976995e82a6f1d7e24e
8 N5003ee4686e1455fb630814d5f749c36
9 N59fa891744a747fb8161614420508606
10 N959f18759f6f4884868074dbf9746ef0
11 Na53461297026418d952344855daf387f
12 Nba67304699ca441987f8de6c07de995f
13 Nbf8ce109622349e6928c4c630f3d50ec
14 Ndc9bf276539c4df99653769f8a687df2
15 Nf23584341470475a801e7342a419bcf7
16 Nfa0d56d7a53d4ed897312e484db5ed70
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Nd17be6aa937844e7b97475b1efab2068
20 schema:citation sg:pub.10.1038/376785a0
21 sg:pub.10.1038/380075a0
22 sg:pub.10.1038/5517
23 sg:pub.10.1038/sj.cdd.4400467
24 sg:pub.10.1038/sj.onc.1202561
25 sg:pub.10.1038/sj.onc.1202702
26 sg:pub.10.1038/sj.onc.1203453
27 sg:pub.10.1038/sj.onc.1203700
28 sg:pub.10.1038/sj.onc.1204282
29 sg:pub.10.1038/sj.onc.1204736
30 schema:datePublished 2005-01
31 schema:datePublishedReg 2005-01-01
32 schema:description Patients with malignant gliomas have a poor prognosis and new treatment paradigms are needed against this disease. TRAIL/Apo2L selectively induces apoptosis in malignant cells sparing normal cells and is hence of interest as a potential therapeutic agent against gliomas. To determine the factors that modulate sensitivity to TRAIL, we examined the differences in TRAIL-activated signaling pathways in glioma cells with variable sensitivities to the agent. Apoptosis in response to TRAIL was unrelated to DR5 expression or endogenous p53 status in a panel of 8 glioma cell lines. TRAIL activated the extrinsic (cleavage of caspase-8, caspase-3 and PARP) and mitochondrial apoptotic pathways and reduced FLIP levels. It also induced caspase-dependent JNK activation, which did not influence TRAIL-induced apoptosis. Because the pro-survival PI3K/Akt pathway is highly relevant to gliomas, we assessed whether Akt could protect against TRAIL-induced apoptosis. Pretreatment with SH-6, a novel Akt inhibitor, enhanced TRAIL-induced apoptosis, suggesting a protective role for Akt. Conversely, TRAIL induced caspase-dependent cleavage of Akt neutralizing its anti-apoptotic effects. These results demonstrate that TRAIL-induced apoptosis in gliomas involves both activation of death pathways and downregulation of survival pathways. Additional studies are warranted to determine the therapeutic potential of TRAIL against gliomas.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N0bb7a0ec6b88429bb412d32c32e10686
37 Nced36380c1b643b2b36a5648637dd167
38 sg:journal.1117236
39 schema:keywords Additional studies
40 Akt
41 Akt inhibition
42 Akt inhibitor
43 Akt pathway
44 Apo2L
45 DR5 expression
46 FLIP levels
47 JNK activation
48 PI3K/Akt pathway
49 SH-6
50 TRAIL-induced apoptosis
51 TRAIL/Apo2L
52 activation
53 agents
54 anti-apoptotic effect
55 apoptosis
56 apoptotic pathway
57 caspase-dependent cleavage
58 cell lines
59 cells
60 cleavage
61 death pathways
62 differences
63 disease
64 downregulation
65 effect
66 endogenous p53 status
67 expression
68 factors
69 glioma cell lines
70 glioma cells
71 gliomas
72 inhibitors
73 interest
74 levels
75 lines
76 malignant cells
77 malignant gliomas
78 mitochondrial apoptotic pathway
79 new treatment paradigm
80 normal cells
81 novel Akt inhibitor
82 p53 status
83 panel
84 paradigm
85 pathway
86 patients
87 poor prognosis
88 potential
89 potential therapeutic agent
90 pretreatment
91 prognosis
92 protective role
93 response
94 results
95 role
96 sensitivity
97 status
98 study
99 survival pathways
100 therapeutic agents
101 therapeutic potential
102 trails
103 treatment paradigm
104 variable sensitivity
105 schema:name TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
106 schema:pagination 233-243
107 schema:productId N1e37e0aad8b1465d9e4d97816d6924cc
108 N3076bba08258430488c19bd8216c73f5
109 N8c8d67088d9f4aa6a186d00f2a0b1e34
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046921353
111 https://doi.org/10.1007/s10495-005-6078-3
112 schema:sdDatePublished 2022-05-20T07:23
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N3534dd9eb878404ea66a46c78e5c5878
115 schema:url https://doi.org/10.1007/s10495-005-6078-3
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N0bb7a0ec6b88429bb412d32c32e10686 schema:volumeNumber 10
120 rdf:type schema:PublicationVolume
121 N134a43afbe6b488a876ae98b42afbcae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name JNK Mitogen-Activated Protein Kinases
123 rdf:type schema:DefinedTerm
124 N15f41fa8e7fb4bcca5ead05acadc489d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Enzyme Activation
126 rdf:type schema:DefinedTerm
127 N1e37e0aad8b1465d9e4d97816d6924cc schema:name pubmed_id
128 schema:value 15711939
129 rdf:type schema:PropertyValue
130 N26b0d07183ab43f19190a4dfa680cf1a schema:affiliation grid-institutes:grid.240145.6
131 schema:familyName Nangia
132 schema:givenName J.
133 rdf:type schema:Person
134 N288d9bad1c1f434590a27b131e05f994 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name MAP Kinase Kinase 4
136 rdf:type schema:DefinedTerm
137 N3076bba08258430488c19bd8216c73f5 schema:name doi
138 schema:value 10.1007/s10495-005-6078-3
139 rdf:type schema:PropertyValue
140 N338d23b582304d10b3d108286e197c7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Tumor Necrosis Factor-alpha
142 rdf:type schema:DefinedTerm
143 N3534dd9eb878404ea66a46c78e5c5878 schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N35bbce0006c94e19a66fc384de39a909 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name TNF-Related Apoptosis-Inducing Ligand
147 rdf:type schema:DefinedTerm
148 N41719eb3db5c425ababbac7eca97320b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Protein-Serine-Threonine Kinases
150 rdf:type schema:DefinedTerm
151 N43a06b49f0244976995e82a6f1d7e24e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Apoptosis Regulatory Proteins
153 rdf:type schema:DefinedTerm
154 N5003ee4686e1455fb630814d5f749c36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Glioma
156 rdf:type schema:DefinedTerm
157 N59fa891744a747fb8161614420508606 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cell Line, Tumor
159 rdf:type schema:DefinedTerm
160 N65fe0211f07144c385dd9a346ec19ba5 rdf:first N26b0d07183ab43f19190a4dfa680cf1a
161 rdf:rest Ndb2a1667793e4bcf9e324c062f37846c
162 N8c8d67088d9f4aa6a186d00f2a0b1e34 schema:name dimensions_id
163 schema:value pub.1046921353
164 rdf:type schema:PropertyValue
165 N959f18759f6f4884868074dbf9746ef0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Proto-Oncogene Proteins c-akt
167 rdf:type schema:DefinedTerm
168 N99368cfd42da4a4d95b41556b5ac27f1 rdf:first sg:person.013375073077.30
169 rdf:rest N65fe0211f07144c385dd9a346ec19ba5
170 Na53461297026418d952344855daf387f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Membrane Glycoproteins
172 rdf:type schema:DefinedTerm
173 Nba67304699ca441987f8de6c07de995f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Apoptosis
175 rdf:type schema:DefinedTerm
176 Nbf8ce109622349e6928c4c630f3d50ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Humans
178 rdf:type schema:DefinedTerm
179 Nced36380c1b643b2b36a5648637dd167 schema:issueNumber 1
180 rdf:type schema:PublicationIssue
181 Nd17be6aa937844e7b97475b1efab2068 rdf:first sg:person.01156403355.42
182 rdf:rest Nfd9562bafd2349ea94f866ed6ab581a3
183 Nd956b177f1734910817a22111e012587 rdf:first sg:person.014354466417.30
184 rdf:rest rdf:nil
185 Ndb2a1667793e4bcf9e324c062f37846c rdf:first sg:person.01352651714.56
186 rdf:rest Nd956b177f1734910817a22111e012587
187 Ndc9bf276539c4df99653769f8a687df2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Mitogen-Activated Protein Kinase Kinases
189 rdf:type schema:DefinedTerm
190 Nf23584341470475a801e7342a419bcf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Proto-Oncogene Proteins
192 rdf:type schema:DefinedTerm
193 Nfa0d56d7a53d4ed897312e484db5ed70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Signal Transduction
195 rdf:type schema:DefinedTerm
196 Nfd9562bafd2349ea94f866ed6ab581a3 rdf:first sg:person.01231612071.24
197 rdf:rest N99368cfd42da4a4d95b41556b5ac27f1
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
202 schema:name Oncology and Carcinogenesis
203 rdf:type schema:DefinedTerm
204 sg:grant.2435611 http://pending.schema.org/fundedItem sg:pub.10.1007/s10495-005-6078-3
205 rdf:type schema:MonetaryGrant
206 sg:grant.2478133 http://pending.schema.org/fundedItem sg:pub.10.1007/s10495-005-6078-3
207 rdf:type schema:MonetaryGrant
208 sg:journal.1117236 schema:issn 1360-8185
209 1573-675X
210 schema:name Apoptosis
211 schema:publisher Springer Nature
212 rdf:type schema:Periodical
213 sg:person.01156403355.42 schema:affiliation grid-institutes:grid.240145.6
214 schema:familyName Puduvalli
215 schema:givenName V. K.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156403355.42
217 rdf:type schema:Person
218 sg:person.01231612071.24 schema:affiliation grid-institutes:grid.240145.6
219 schema:familyName Sampath
220 schema:givenName D.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231612071.24
222 rdf:type schema:Person
223 sg:person.013375073077.30 schema:affiliation grid-institutes:grid.240145.6
224 schema:familyName Bruner
225 schema:givenName J. M.
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30
227 rdf:type schema:Person
228 sg:person.01352651714.56 schema:affiliation grid-institutes:grid.240145.6
229 schema:familyName Xu
230 schema:givenName R.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352651714.56
232 rdf:type schema:Person
233 sg:person.014354466417.30 schema:affiliation grid-institutes:None
234 schema:familyName Kyritsis
235 schema:givenName A. P.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014354466417.30
237 rdf:type schema:Person
238 sg:pub.10.1038/376785a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022545215
239 https://doi.org/10.1038/376785a0
240 rdf:type schema:CreativeWork
241 sg:pub.10.1038/380075a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029942479
242 https://doi.org/10.1038/380075a0
243 rdf:type schema:CreativeWork
244 sg:pub.10.1038/5517 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010598958
245 https://doi.org/10.1038/5517
246 rdf:type schema:CreativeWork
247 sg:pub.10.1038/sj.cdd.4400467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015301816
248 https://doi.org/10.1038/sj.cdd.4400467
249 rdf:type schema:CreativeWork
250 sg:pub.10.1038/sj.onc.1202561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046556077
251 https://doi.org/10.1038/sj.onc.1202561
252 rdf:type schema:CreativeWork
253 sg:pub.10.1038/sj.onc.1202702 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036436500
254 https://doi.org/10.1038/sj.onc.1202702
255 rdf:type schema:CreativeWork
256 sg:pub.10.1038/sj.onc.1203453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050239579
257 https://doi.org/10.1038/sj.onc.1203453
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/sj.onc.1203700 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014822552
260 https://doi.org/10.1038/sj.onc.1203700
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/sj.onc.1204282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014003480
263 https://doi.org/10.1038/sj.onc.1204282
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/sj.onc.1204736 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011680283
266 https://doi.org/10.1038/sj.onc.1204736
267 rdf:type schema:CreativeWork
268 grid-institutes:None schema:alternateName Department of Neurology, University of Ioaninna, Ioaninna, Greece
269 schema:name Department of Neurology, University of Ioaninna, Ioaninna, Greece
270 rdf:type schema:Organization
271 grid-institutes:grid.240145.6 schema:alternateName Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA
272 Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA
273 Pathology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA
274 schema:name Departments of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA
275 Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA
276 Pathology, The University of Texas M. D. Anderson Cancer Center, 7700, Houston, TX, USA
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...